Alzheimer's & Cognition
Conference Coverage
Transient epileptic amnesia: Rare, treatable, and easy to miss
LOS ANGELES – A review of cases finds that neuroimaging with FDG-PET reveals focal abnormalities
Conference Coverage
Targeting inactivity, mood, and cognition could be key to reducing OA mortality
LIVERPOOL, ENGLAND – OA was associated with a 15% increased risk of mortality in the general population.
Cases That Test Your Skills
Sudden-onset memory problems, visual hallucinations, and odd behaviors
Ms. D, age 62, is disoriented, distractible, tearful, and tangential. She reports that 'aerialists' are climbing through her windows at night and...
Savvy Psychopharmacology
Ruling out delirium: Therapeutic principles of withdrawing and changing medications
Ms. M, age 71, was diagnosed with Alzheimer’s disease several months ago and her clinical presentation and Mini-Mental Status Exam score of 22...
From the Journals
Anticholinergics’ link to dementia calls for vigilance in elderly
The associations seen were “moderate” but reflect an “appreciable risk” for patients.
Cases That Test Your Skills
Worsening agitation and hallucinations: Could it be PTSD?
Mr. G, age 57, presents with confusion, hallucinations, and agitation. He has a history of PTSD, depression, anxiety, and lung cancer. What could...
From the Journals
Targeting obesity could slow brain aging in psychosis
"The brains of participants with [first-episode psychosis] appeared on average 2.64 years older than their chronological age."
From the Editor
Are you neuroprotecting your patients? 10 Adjunctive therapies to consider
Recurrent episodes of psychosis, mania, or depression have been shown to be potentially neurodegenerative and associated with neurotoxicity due...
Daily News Podcast
MDedge Daily News: Diabetes patients ignore a deadly risk
And a three-in-one pill could change hypertension treatment.
Video
Promoting your older patient’s healthy ‘brain aging’
George T. Grossberg, MD, provides advice for your patients and their family that may help prevent or delay the onset of Alzheimer’s disease.
From the Journals
Alzheimer’s: Biomarkers, not cognition, will now define disorder
This new way of classifying AD may change the way doctors and patients talk about the disease – and, one day, could change treatment.
